Results 11 to 20 of about 5,730 (206)

Conformational Trajectory of the Molecular Chameleon Grazoprevir From Formulation to Target-Bound. [PDF]

Chemistry
ABSTRACT Macrocycles represent a promising class of beyond‐rule‐of‐5 (bRo5) therapeutics, capable of targeting proteins traditionally considered undruggable by conventional small molecules. Macrocycles exhibit intrinsic flexibility and often display a “chameleon‐like” ability to adapt to their environment, thereby enhancing their oral bioavailability ...
Wieske LHE, Bu G, Erdélyi M, Kihlberg J, Gonen T, Danelius ER.   +5 more
europepmc   +2 more sources

Simeprevir Capsules [PDF]

Hospital Pharmacy, 2014
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Cada, Dennis J, Levien, Terri L, Baker, Danial E   +2 more
openaire   +3 more sources

Polymorphic Structure Determination of the Macrocyclic Drug Paritaprevir by MicroED. [PDF]

Adv Biol (Weinh)
Paritaprevir has been widely used for treating chronic hepatitis C virus infection. It is a macrocyclic drug whose structure has long been unavailable. Microcrystal electron diffraction is applied to determine two polymorph structures which are investigated for potential binding mode to the target protease.
Bu G, Danelius E, Wieske LHE, Gonen T.
europepmc   +2 more sources

Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C. [PDF]

, 2015
Sofosbuvir and simeprevir are used for the treatment of chronic hepatitis C (HCV) genotype 1. Both drugs have been well-tolerated, with diarrhea noted in 6% cases with sofosbuvir, 16% with sofosbuvir plus simeprevir, and 0% with simeprevir.
Jakab, Simona, Lim, Joseph K, Mitchell, Kisha A, Oikonomou, Ioannis, Sarkar, Souvik   +4 more
core   +1 more source

Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents [PDF]

, 2014
Hepatitis C virus (HCV) is transmitted between hepatocytes via classical cell entry but also uses direct cell-cell transfer to infect neighboring hepatocytes.
A Owsianka, A Sigal, Aleem Siddiqui, Arvind H. Patel, AS Lok, AW Tarr, B Bartolini, B Sainz Jr, C Hezode, C Lee, C Nathan, C Sarrazin, CL Brimacombe, CM Lange, CT Jones, D Masson, D Trono, EJ Gane, Eric Soulier, F Kuonen, F Poordad, F Poordad, Fei Xiao, François Habersetzer, G Koutsoudakis, H Kwon, H Yan, H Zhu, Heidi Barth, I Fofana, I Fofana, I Fofana, IA Abela, IM Jacobson, Isabel Fofana, J Grove, J Lupberger, J Witteveldt, J Zhong, Jens Bukh, JG McHutchison, JM Gottwein, JM Gottwein, JM Pawlotsky, JM Pawlotsky, JM Pawlotsky, JM Timpe, L Rong, L Zona, Laura Heydmann, LW Meredith, MB Zeisel, MB Zeisel, Michel Doffoël, Mirjam B. Zeisel, MN Zahid, MS Sulkowski, MT Catanese, N Shi, O Lenz, P Zhong, PM Trembling, Q Sattentau, S Haid, T Pietschmann, T Pietschmann, T Wakita, Thomas F. Baumert, TJ Liang, TK Scheel, V Soriano, VD Cataldo, ZY Keck   +72 more
core   +7 more sources

Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C. [PDF]

, 2017
Background and Aims: Recurrent infection of hepatitis C virus (HCV) in liver transplant (LT) recipients is universal and associated with significant morbidity and mortality.
Bau, Sherona N, Busuttil, Ronald W, Choi, Gina, Durazo, Francisco A, El-Kabany, Mohammed M, Esmailzadeh, Negin L, Fong, Tiffany M, Grotts, Jonathan, Han, Steven-Huy B, Jimenez, Melissa A, Kachadoorian, Caterina A, Kang, Susan, Mai, Michelle H, Ramirez, Samantha D, Rheem, Justin, Saab, Sammy   +15 more
core   +1 more source

Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort. [PDF]

, 2018
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. HCV cure has been linked to improved patient outcomes. In the era of direct-acting antivirals (DAAs), HCV cure has become the goal, as defined by sustained virological response ...
Benhammou, Jihane N, Bhattacharya, Debika, Dixit, Ram, Dixit, Vivek, Dong, Tien S, Han, Steven B, Jackson, Samuel, Kawamoto, Jenna, May, Folasade P, Pisegna, Joseph R   +9 more
core   +1 more source

Diminishing Use of Liver Biopsy among Liver Transplant Recipients for Hepatitis C. [PDF]

, 2017
Background and Aims: Hepatitis C virus (HCV) cirrhosis is the leading indication for liver transplantation in the United States and recurrent HCV following liver transplantation is a major cause of allograft loss and mortality.
Aby, Elizabeth, Agopian, Vatche, Busuttil, Ronald W, French, Samuel W, Grotts, Jonathan F, Jimenez, Melissa A, Saab, Sammy   +6 more
core   +1 more source

Timing for treatment of HCV recurrence after liver transplantation: the earlier the better. [PDF]

, 2016
HCV is the leading cause of death from liver disease and is the most common indication for a liver transplantation. Although HCV is a widespread health problem, disease management is particularly challenging in several key subpopulations, including liver
Burra, Patrizia, Russo, Francesco Paolo, Zanetto, A   +2 more
core   +1 more source

Simultaneous spectrofluorimetic determination of remdesivir and simeprevir in human plasma

Scientific Reports, 2022
As new infectious mutations of SARS-CoV-2 emerged throughout the world, innovative therapies to counter the virus-altered drug sensitivities were urgently needed.
Mona E. El Sharkasy, Manar M. Tolba, Fathalla Belal, Mohamed I. Walash, Rasha Aboshabana   +4 more
doaj   +1 more source